Clinical Trial Update: A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and systems biology response of the ChAd3-EBO-Z Ebola vaccine has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• ChAd3-EBO-Z

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Ebola Disease, Immunisation | Phase 1 | Status: COMPLETED | Results posted: 2021-06-02